RGENRepligen Corporation
$173.84+42% 1Y
$173.84
$102.8752 weeks$194.62
The financials
Repligen Corporation by the numbers
Repligen Corporation (RGEN) reported revenue of $204M in Q2 2026 (quarter ended Jun 30, 2026), up 12% from the same quarter a year earlier. That came with a gross margin of 54% and net income of $5.0M (2.5% of revenue). For the full year FY2025, revenue was $738M (+16% year on year) and net income $49M. The next results filing is expected around Oct 27, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $204M | $182M | +12% |
| Gross profit | $110M | $93M | +18% |
| Operating income | $14M | $14M | +0.6% |
| Net income | $5.0M | $15M | −66% |
| Diluted EPS | $0.09 | $0.26 | −65% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $43.0K (-2.3%)
Royalty grew +16% year on year
Segment Latestquarter on quarteryear on year
- Royalty$43.0K$43.0Kquarter on quarter -2.3%year on year +16%-2.3%+16%
Medical Instruments & Supplies
Ranks #11 of 21 by RyuScore